Monoclonal Antibodies for COVID-19
An Update on Best Practices
How has the BA.2.12.1 COVID-19 subvariant changed clinical practice?
Real-World Best Practices in a COVID-19 Clinic
Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.
Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.
Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]
Neutralization escape by the SARS-CoV-2 Omicron variants BA.2.12.1 and BA.4/BA.5.
Hachmann NP, Miller J, Collier A-rY, et al. medRxiv. 2022. [Epub ahead of print]
At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.
Levin M, Ustianowski A, De Wit S, et al. N Engl J Med. 2022. [Epub ahead of print]
Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.
Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.
Disparities in COVID-19 monoclonal antibody delivery: a retrospective cohort study.
Wu EL, Kumar RN, Moore WJ, et al. J Gen Intern Med. 2022:1-9.
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants.
Yu J, Collier A-RY, Rowe M, et al. N Engl J Med. 2022;386(16):1579-1580.
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Clinician Resources
Federal response to COVID-19: monoclonal antibody clinical implementation guide.
Department of Health and Human Services (DHHS).
Fact Sheet for Healthcare Providers: Emergency Use Authorization for bebtelovimab.
US Food and Drug Administration (FDA).
Fact Sheet for Healthcare Providers: Emergency Use Authorization of EVUSHELD™ (tixagevimab/cilgavimab).
FDA.
OpenData Portal.
NIH.
Patient Resources
Talking with patients about monoclonal antibodies for COVID-19: tips and frequently asked questions.
DHHS.
Monoclonal Antibodies for COVID-19.
Lloyd EC, Gandhi TN, Petty LA. JAMA. 2021;325(10):1015.
Current Evidence and Guidelines for Anti-SARS-CoV-2 Monoclonal Antibodies
Module 1
| Faculty: | Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH |
| Release: | 06/07/2022 |
| Expiration: | 06/07/2023 |
Real-World Use of Anti-SARS-CoV-2 Monoclonal Antibodies
Module 2
| Faculty: | Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH |
| Release: | 06/07/2022 |
| Expiration: | 06/07/2023 |
